Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1928z-GLUT3 CAR T cells
- Development stage
- Preclinical
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
1928z-GLUT3 CAR T cells are an experimental cellular immunotherapy developed at Memorial Sloan Kettering Cancer Center. The therapy consists of T cells engineered with a second-generation chimeric antigen receptor (CAR) targeting CD19, utilizing the clinically validated 19-28z construct which incorporates a CD28 costimulatory domain and a CD3-zeta signaling domain. These cells are further modified to constitutively overexpress the glucose transporter GLUT3 (SLC2A3) to theoretically enhance metabolic fitness and glucose uptake within the competitive, glucose-depleted tumor microenvironment. However, preclinical research presented at ASH 2023 indicated that GLUT3 overexpression, unlike GLUT1, resulted in reduced T-cell viability and impaired therapeutic efficacy in models of B-cell acute lymphoblastic leukemia (ALL), such as NALM6.
- Other names
- GLUT3-overexpressing 19-28z CAR T cellsGLUT-3-overexpressing 19-28z CAR T cellsGLUT 3-overexpressing 19-28z CAR T cellsGLUT3-overexpressing CD19 CAR T cellsGLUT-3-overexpressing CD19 CAR T cellsGLUT 3-overexpressing CD19 CAR T cells
02
Targets
CD19 (B lymphocyte antigen CD19)SLC2A3 (Glucose transporter type 3)
Beyond the preview
Go deeper on 1928z-GLUT3 CAR T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 1928z-GLUT3 CAR T cells.